Acadia Pharmaceuticals Inc. announced that the company has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer
